No Data
No Data
Lyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial Outcomes
Express News | Lyra Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Sales Results
BTIG Maintains Lyra Therapeutics(LYRA.US) With Hold Rating
Lyra Therapeutics | 10-Q: Q3 2024 Earnings Report
Lyra Therapeutics | 8-K: Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
No Data
No Data
